Back to Awarded Treatment Trials
Awarded Trial: 03T-471
Grant ID
03T-471
Illness
Schizophrenia
Primary Drug/Intervention
Epigallocatechin Gallate (EGCG)
Primary Dosage
up to 1600mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Berger
Sample Size
40
Duration of Study Period for Each Subject
10 weeks
Outcome Measurements
CGI, PANSS, SANS, HAM-D, HAM-A, AIMS
Results
Epigallocatechin gallate (EGCG) is an ingredient of green tea and thought to have effects on nitric acid and glutamate receptors. It is available in health food stores. The researchers randomized 34 patients with schizophrenia to EGCG 1600 mg/d or placebo for 8 wks. There were 9 dropouts and 25 completers. Both groups improved, and there was no statistical difference between them. It was thus a negative trial.
Publication
N/A
Link
N/A
PI Name
S. Paul Berger
Degree
MD
Center
N/A
Institution
Portland Veterans Affairs Medical Center
Address
3710 SW US Veterans Hospital Road R&D 64
City or Town
Portland
State or Province
OR
Zip or Postal Code
97239
Country
USA
Email Address
bergerp@ohsu.edu